DNA damage response specialist Artios Ltd. has closed an oversubscribed $115 million series D after delivering positive phase I/IIa data for its two lead programs.

Fresh cash infusions are on the way for European biotech after two leading venture capital firms announced large new funds. Asset-focused Medicxi has closed an oversubscribed €500 million (US$580 million) fund, while Sofinnova Partners exceeded its target of €500 million to close its Capital XI fund at €650 million (US$753.5 million).

While Europe’s biotech sector continues to face headwinds, med tech appears to be weathering the storm more effectively. Uncertainty in the U.S., heightened competition from China and a persistent lack of capital are all impacting the investment landscape, delegates heard at the LSX Investival Showcase in London.

Mitorx Therapeutics Ltd. has raised £5.5 million (US$7.2 million) in a pre-series A round to advance its lead mitochondrial-targeted program, Myo-004, through clinical candidate selection.

Cornerstone Robotics Ltd. raised an oversubscribed $200 million series D round to accelerate commercialization of its flagship product, the Sentire Endoscopic Surgical System.